XtenCHO™ High-Density Expression System

The XtenCHO™ high-density expression system developed by AtaGenix demonstrates exceptional advantages in proliferation and yield for therapeutic antibody production. Cells cultured using this system maintained high cell density and viability over 15 days, ensuring a healthy growth environment. The yields of various antibodies highlight the system's adaptability, delivering robust production efficiency across different therapeutic antibodies. These strengths provide strong support for efficient and stable therapeutic antibody production.

Fig 1. Trends in Cell Density and Viability Over a 15-Day Culture Period for Different Cell Lines (6-B to 20-F)

Cell Density: Over the 15-day culture period, most cell lines exhibited a steady increase in cell density, indicating strong proliferative potential and excellent growth conditions. However, variations were observed among different cell lines, with some showing rapid density increases while others were more moderate.

Cell Viability: Nearly all cell lines maintained high viability levels, close to 100%, throughout the culture process, reflecting healthy cellular states and high proliferative activity. However, a slight decline in viability was noted in certain cell lines towards the later stages of the culture, potentially influenced by culture conditions or inherent cell characteristics.

Fig 2. Yields of 11 Different Therapeutic Antibodies (mg/L)

Antibody Yield Variations: Significant differences were observed in the yields of various antibodies. Antibody 3 achieved the highest yield, nearing 1500 mg/L, while antibodies 1, 7, and 8 exhibited lower yields, below 100 mg/L. These variations may be attributed to factors such as antibody structure and the adaptability of the expression system.

Overall Trend: Apart from a few exceptions, the majority of antibody yields ranged between 500-1000 mg/L, demonstrating the system’s high production efficiency for most therapeutic antibodies.

Highlights:

• The XtenCHO™ high-density expression system ensures optimal cell health and supports robust proliferation over extended culture periods.
• The system delivers high antibody yields, with most antibodies exceeding 500 mg/L, showcasing its exceptional adaptability to various antibody types.
• These capabilities make the XtenCHO™ system a reliable solution for therapeutic antibody production, driving efficiency and scalability in research and manufacturing environments.